Template:COVID-19 vaccine candidates

From blackwiki
Jump to navigation Jump to search

Template:VEFriendly

COVID‑19 vaccine candidates in Phase I–II trials
(Most advanced clinical research highlighted in green.)
COVID-19 vaccine candidates()
Vaccine candidate

(Developer/Sponsor)

Technology Phase of trial

(Participants)

Adverse effects Immune response Location Duration References/Notes
Ad5-nCoV

(CanSino Biologics, Institute of Biotechnology of the Academy of Military Medical Sciences)

Recombinant adenovirus type 5 vector Phase II interventional trial for dosing and side effects (500) China March 2020 to December 2020 Clinical and manufacturing partnership with the National Research Council of Canada and Canadian Center for Vaccinology, Halifax, Nova Scotia[1][2][3]
Phase I (108) Moderate over seven days; fever, pain, fatigue[4] Moderate antibody and T-cell responses[4] [4][5]
ChAdOx1 nCoV-19

(University of Oxford)

Adenovirus vector Phase I–II, randomized, placebo-controlled, multiple sites (1000) United Kingdom April 2020 to May 2021 [6][7]
BNT162 (a1, b1, b2, c2)

(BioNTech, Fosun Pharma, Pfizer)

RNA Phase I–II of four vaccines, randomized, placebo-controlled, dose-finding, vaccine candidate-selection (7600) Germany
United States
April 2020 to May 2021 [8][9][10]
unnamed

(Sinovac Biotech)

Inactivated SARS-CoV-2 virus Phase I–II randomized, double-blinded, single-center, placebo-controlled in Xuzhou (744); Phase I–II in Renqiu (422) China •April 2020 to December 2020 in Xuzhou
•May to July 2020 in Renqiu
[11][12]
INO-4800

(Inovio Pharmaceuticals, CEPI, Korea National Institute of Health, International Vaccine Institute)

DNA plasmid delivered by electroporation Phase I–II (40) United States
South Korea
April 2020 to November 2020 South Korean Phase I–II in parallel with Phase I in the U.S.[13][14]
mRNA-1273

(Moderna, US National Institute of Allergy and Infectious Diseases)

Lipid nanoparticle dispersion containing messenger RNA Phase I (45) United States March 2020 to Spring-Summer 2021 [15][16][17]
COVID-19/aAPC

(Shenzhen Geno-Immune Medical Institute)

Lentiviral vector, pathogen-specific artificial antigen presenting dendritic cells Phase I (100) China March 2020 to 2023 [15][18]
LV-SMENP-DC

(Shenzhen Geno-Immune Medical Institute)

Lentiviral minigene vaccine, dendritic cells modified with lentiviral vector Phase I (100) China March 2020 to 2023 [15][19]
bacTRL-Spike

(Symvivo Corporation, University of British Columbia, Dalhousie University)

DNA, bacterial medium (oral) Phase I (84) Canada April 2020 to December 2021 [20]
unnamed

(Beijing Institute of Biological Products, Wuhan Institute of Biological Products)

Inactivated COVID-19 virus (vero cells) Phase I (288) China April 2020 to November 2021 Has Phase II design registered for > 1000 participants, including children, not yet recruiting[21][22]
NVX-CoV2373

(Novavax)

SARS-CoV-2 recombinant spike protein nanoparticle with adjuvant Phase I (131) Australia May 2020 to July 2021 [23]
  1. Clinical trial number NCT04341389 for "A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)" at ClinicalTrials.gov
  2. "The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19". National Research Council, Government of Canada. 2020-05-12. Retrieved 2020-05-22.
  3. Ryan, Haley (2020-05-16). "Canada's first COVID-19 vaccine trials approved for Halifax university". CBC News. Retrieved 2020-05-22.
  4. 4.0 4.1 4.2 Zhu, Feng-Cai; Li, Yu-Hua; Guan, Xu-Hua; Hou, Li-Hua; Wang, Wen-Juan; Li, Jing-Xin; Wu, Shi-Po; Wang, Bu-Sen; Wang, Zhao; Wang, Lei; Jia, Si-Yue (2020-05-22). "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial". The Lancet. doi:10.1016/S0140-6736(20)31208-3. ISSN 0140-6736.
  5. Clinical trial number NCT04313127 for "A Phase I Clinical Trial in 18-60 Adults" at ClinicalTrials.gov
  6. "A phase I/II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers". Health Research Authority, UK National Health Service. Retrieved 2020-05-10.
  7. Clinical trial number NCT04324606 for "A Study of a Candidate COVID-19 Vaccine (COV001)" at ClinicalTrials.gov
  8. "EudraCT Number 2020-001038-36". EU Clinical Trials Register. European Union. Retrieved 22 April 2020.
  9. "Mainzer Unternehmen Biontech testet Corona-Impfstoff". swr.online (in German). SWR. 22 April 2020. Retrieved 22 April 2020.
  10. Clinical trial number NCT04368728 for "Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults" at ClinicalTrials.gov
  11. Clinical trial number NCT04352608 for "Safety and Immunogenicity Study of 2019-nCoV Vaccine (Inactivated) for Prophylaxis SARS CoV-2 Infection (COVID-19)" at ClinicalTrials.gov
  12. "Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. US National Library of Medicine, National Institutes of Health. Retrieved 13 May 2020.
  13. "IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea". International Vaccine Institute. 2020-04-16. Retrieved 2020-04-23.
  14. Clinical trial number NCT04336410 for "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers" at ClinicalTrials.gov
  15. 15.0 15.1 15.2 Thanh Le, Tung; Andreadakis, Zacharias; Kumar, Arun; Gómez Román, Raúl; Tollefsen, Stig; Saville, Melanie; Mayhew, Stephen (9 April 2020). "The COVID-19 vaccine development landscape". Nature Reviews Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591. Unknown parameter |name-list-style= ignored (help)
  16. "NIH clinical trial of investigational vaccine for COVID-19 begins". US National Institutes of Health. 16 March 2020. Retrieved 17 March 2020.
  17. Clinical trial number NCT04283461 for "Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection" at ClinicalTrials.gov
  18. Clinical trial number NCT04299724 for "Safety and Immunity of Covid-19 aAPC Vaccine" at ClinicalTrials.gov
  19. Clinical trial number NCT04276896 for "Immunity and Safety of Covid-19 Synthetic Minigene Vaccine" at ClinicalTrials.gov
  20. Clinical trial number NCT04334980 for "Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19" at ClinicalTrials.gov
  21. "A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated novel coronavirus pneumonia vaccine (vero cells)". Chinese Clinical Trial Registry. 2020-04-11. Retrieved 2020-04-25.
  22. "Draft landscape of COVID-19 candidate vaccines – 23 April 2020" (PDF). World Health Organization. 2020-04-23. Retrieved 2020-04-25.
  23. Clinical trial number NCT04368988 for "Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant" at ClinicalTrials.gov